Latest news about Vivanza Biosciences
Vivanza Biosciences
1.80
+0.05(+2.86%)
Company Performance:
View Company Insights1D+2.86%
1M0.00%
6M-12.62%
1Y-13.04%
5Y-84.75%
More news about Vivanza Biosciences
29Jun 26
Vivanza Biosciences signs strategic cooperation agreement for Kyrgyz film project
Vivanza Biosciences Limited has entered into a Strategic Cooperation, Investment & Technology Transfer Agreement with Mr. Kalybek Uulu Bekturgan for a Plastic Film Manufacturing Project in the Kyrgyz Republic. The non-binding agreement encompasses technology transfer, investment facilitation, and potential joint venture formation. No monetary consideration was paid initially, and the company expects the move to enhance its international presence and export markets.
18Jun 26
Vivanza Biosciences appoints Hemant Amrish Parikh as director
Vivanza Biosciences Limited announced the appointment of Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director for a term of five years effective June 18, 2026, pending shareholder approval. Concurrently, the Board appointed M/s. Dharti Shah & Co. as the Internal Auditor for the financial year 2026-2027.
09May 26
Vivanza Biosciences Publishes FY26 Financial Results Advert
Vivanza Biosciences Limited published an advertisement for its audited FY26 financial results in newspapers on May 9, 2026, as per SEBI regulations. The company achieved a turnaround with a standalone net profit of ₹37.50 lacs and consolidated net profit of ₹39.44 lacs, alongside a significant surge in revenue to ₹11,223.10 lacs on a standalone basis.
08May 26
Vivanza Biosciences Declares Non-Applicability of Related Party Transaction Disclosure for Quarter and Year Ended March 31, 2026
Vivanza Biosciences Limited has notified BSE Limited of the non-applicability of the Related Party Transactions disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31st March, 2026. The exemption is based on Regulation 15(2), which applies to listed entities with paid-up equity share capital not exceeding Rs. 10 Crores and net worth not exceeding Rs. 25 Crores. As on 31st March, 2025, the company's paid-up equity share capital was Rs. 4,00,00,000/- and its net worth was Rs. 4,02,03,752.40/-, both within the prescribed thresholds. The company has committed to comply with the regulation within six months once it becomes applicable.
15Apr 26
Vivanza Biosciences Limited Exempt from Annual Secretarial Compliance Report for FY26 Under SEBI Regulation 24A
Vivanza Biosciences Limited has informed BSE about its exemption from submitting the Annual Secretarial Compliance Report for FY26 under SEBI Regulation 24A. The company qualifies for exemption with paid-up share capital of Rs. 4 crore and net worth of Rs. 4,02,03,752.40, both falling below the regulatory thresholds of Rs. 10 crores and Rs. 25 crores respectively. This exemption is available under Regulation 15(2) of SEBI (LODR) Regulations, 2015, for smaller listed entities.
14Apr 26
Vivanza Biosciences Files Non-Applicability Statement for SEBI LODR Regulation 32 Compliance
Vivanza Biosciences Limited filed a non-applicability statement with BSE Limited on 14th April, 2026, regarding SEBI LODR Regulation 32 compliance. The company confirmed it has not raised funds through Public Issue, Rights Issue, Preferential Issue, or QIP, making the deviation statement requirement non-applicable. The communication was signed by Company Secretary Chaitra Arora and demonstrates the company's regulatory compliance commitment.
09Apr 26
Vivanza Biosciences Limited Files Annual SEBI SAST Disclosure for FY26
Vivanza Biosciences Limited submitted its annual SEBI SAST disclosure for FY26 ended March 31, 2026, to BSE Limited on April 9, 2026. Promoters Parth H. Parikh and Hemant A. Parikh declared holdings of 79,07,622 shares and 1,00,211 shares respectively, with both confirming no share encumbrance during the financial year. The disclosure ensures compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.
09Apr 26
Vivanza Biosciences Limited Confirms Non-Applicability of Large Corporate Status for FY26 Compliance
Vivanza Biosciences Limited has confirmed to BSE Limited that it does not qualify as a "Large Corporate" under regulatory criteria as of March 31, 2026. This status exempts the company from filing Initial Disclosure requirements under Annexure A and Annexure XII A for FY26, as mandated by various SEBI and BSE circulars related to debt securities fund raising by large corporates.
07Apr 26
Vivanza Biosciences Submits SEBI Confirmation Certificate for Q4 FY26
Vivanza Biosciences Limited submitted its confirmation certificate under SEBI Regulation 74(5) for Q4 FY26 to BSE Limited on April 7, 2026. The certificate, issued by Registrar and Transfer Agent Purva Sharegistry (I) Private Limited, covers the quarter ended March 31, 2026. The dematerialization report shows no share certificates were processed during the period from January 1, 2026 to March 31, 2026, with all entries marked as 'NIL'.
17Mar 26
Vivanza Biosciences Director Hemant Parikh Resigns Due to Personal Reasons
Vivanza Biosciences Limited formally announced the resignation of Mr. Hemant Amrish Parikh as Non-Executive Director, effective from close of business hours on March 17, 2026. The resignation was attributed to personal reasons with confirmation that no material concerns exist beyond those stated, ensuring full regulatory compliance under SEBI Listing Obligations.
18Dec 25
Vivanza Biosciences Formalizes MOA Amendment for Packaging Business Expansion
Vivanza Biosciences has officially informed BSE about the approved amendment to its Memorandum of Association for expanding into plastic polymer films and packaging materials manufacturing. The company received overwhelming 99.90% shareholder approval through postal ballot, enabling diversification from biosciences into comprehensive packaging solutions including PE/PP bags, paper bags, and flexible packaging materials for various industries.
11Nov 25
Vivanza Biosciences Reports Q2 Results, Appoints New Company Secretary, Plans Business Expansion
Vivanza Biosciences Limited announced key developments in its board meeting on November 11, 2025. The company reported Q2 FY2026 revenue of Rs. 373.18 lacs and profit before tax of Rs. 48.06 lacs. CS Chaitra Arora was appointed as the new Company Secretary and Compliance Officer, replacing CS Siddhi Shah who resigned. The board proposed expanding the business to include manufacturing of plastic polymer films, plastic bags, paper bags, and flexible packaging materials. A postal ballot process has been initiated for shareholder approval of the proposed changes to the Memorandum of Association.
28Oct 25
Vivanza Biosciences Promoter Reduces Stake by 3.07% Through Market Transaction
Parth H. Parikh, a promoter of Vivanza Biosciences Limited, sold 12,28,781 shares (3.07% of total share capital) in an on-market transaction on October 29, 2024. This reduced his shareholding from 31.58% to 28.50%. The company's total equity share capital stands at 40,000,000 shares with a face value of Rs. 1 per share.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Laurus Labs
Aurobindo Pharma
1,910.00
(+0.40%)
8,496.00
(-1.17%)
4,886.50
(-0.20%)
1,437.90
(+0.40%)
1,103.80
(-1.45%)
2,188.00
(-0.63%)
1,190.00
(+1.30%)
2,374.50
(-0.40%)
1,801.00
(-0.06%)
1,608.00
(-0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
